St. Jude Medical Inc. announced preliminary results from the ILUMIEN I trial and final results from the ILUMIEN II clinical study. Taken together, the findings from both studies show that with resolution up to 10 times higher than intravascular ultrasound (IVUS), optical coherence tomography (OCT) imaging can help improve stent selection and deployment, better support clinical decision-making and improve patient outcomes.

According to a new study, small changes in quality improvement procedures enabled clinicians to use magnetic resonance imaging (MRI) scans to diagnose stroke patients before giving acute treatment, within 60 minutes of arrival. MRI scans provide detailed images but take longer to complete than computed tomography (CT) scans, which are commonly used in most centers.

A study in the May issue of the International Journal of Cardiovascular Imaging examines the ability of the EchoInsight software to achieve quantitative assessment of the right ventricle (RV). The study, “Semi-automated Echocardiographic Quantification of Right Ventricular Size and Function," was published by Diego Medvedofsky, Karima Addetia, Roberto Lang, Victor Mor-Avi, et al.

Significantly fewer renal and cardiac events are associated with angioplasty procedures using isosmolar contrast medium (IOCM) agent Visipaque (iodixanol) than those using low-osmolar contrast media (LOCM), according to new data presented at EuroPCR 2015.

New clinical data from two different studies show the IN.PACT Admiral drug-coated balloon from Medtronic plc successfully treated long lesions in the superficial femoral and popliteal arteries. The data was presented at EuroPCR 2015 during the “Hot line” session on “Peripheral interventions.”

Direct Flow Medical Inc. announced positive two-year data from the DISCOVER CE Mark Trial studying its Direct Flow Medical Transcatheter Aortic Valve System at the EuroPCR conference in Paris, France. Demonstrating excellent patient outcomes with few complications, the two-year data were presented by Antonio Colombo, M.D., Ph.D., from the Ospedale San Raffaele in Milan, Italy.

The Phase C results of the ProMRI Clinical Study were presented at the late-breaking clinical trial session of the Heart Rhythm Society (HRS) 2015 meeting.

Biotronik announced that since the launch of the ProMRI Eluna pacemaker system in late March 2015, 60 percent of pacing devices sold by the company are approved for use during magnetic resonance imaging (MRI) scans. The announcement was made at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions, May 13-16 in Boston.